Clinical Trial: TLR9 Immunotherapy for Peritoneal Carcinomatosis

U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07658196) titled 'TLR9 Immunotherapy for Peritoneal Carcinomatosis' on May 06.

Brief Summary: The goal of this clinical trial is to determine the safety and efficacy of of ACM-CpG for inoperable peritoneal metastases or malignant ascites. The main questions it aims to answer are:

* To determine the safety and maximum tolerated dose (MTD) or optimal biologic dose (OBD) of intraperitoneal injection(s) of ACM-CpG for inoperable peritoneal metastases or malignant ascites? Researchers will assign treatment levels using escalating doses of ACM-CpG Therapy.

Participants will:

* Will receive at least one dose of ACM-CpG therapy on Day 1 of a 28-day treatm...